{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.34","value":"1.38"}]}],"title":"Physical Functioning (N=206)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.89","value":"2.03"}]}],"title":"Role-Physical (N=208)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.99","value":"0.94"}]}],"title":"Bodily Pain (N=206)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.03","value":"1.31"}]}],"title":"General Health Perception (N=208)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.47","value":"1.68"}]}],"title":"Vitality (N=208)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.21","value":"0.52"}]}],"title":"Social Functioning (N=208)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.22","value":"1.75"}]}],"title":"Role-Emotional (N=205)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.45","value":"0.91"}]}],"title":"Mental Health Index (N=208)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.51","value":"1.49"}]}],"title":"Physical Component Summary (N=200)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.80","value":"1.06"}]}],"title":"Mental Component Summary (N=200)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"292"}],"units":"Participants"}],"description":"The SF-36 is a widely used generic health-related quality of life measure. It has 36 questions with 8 domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Items are scored from 0 to 100 with higher scores indicating better health status.","dispersionType":"Standard Deviation","groups":[{"description":"Romiplostim administered to adult participants subcutaneously weekly at doses up to 30 µg/kg based on platelet counts. After Amendment 1 the maximum weekly dose was reduced to 15 µg/kg, and after Amendment 2 the maximum weekly dose was reduced to 10 µg/kg. However, participants enrolled prior to Amendment 2 who were receiving \\>10 µg/kg were permitted to remain on that higher dose, but could not increase their dose. In addition, if the participant's dose was decreased, it could not be increased to \\>10 µg/kg.","id":"OG000","title":"Romiplostim in Adults"}],"paramType":"MEAN","populationDescription":"Full analysis set with available data. Patient reported outcomes were only analyzed in adult participants.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 48","title":"Change From Baseline in Short Form 36 (SF-36)","type":"SECONDARY","unitOfMeasure":"scores on a scale"}